mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions
<jats:p>The successful development of several coronavirus disease 2019 (COVID-19) vaccines has substantially reduced morbidity and mortality in regions of the world where the vaccines have been deployed. However, in the wake of the emergence of viral variants that are able to evade vaccine-ind...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
American Association for the Advancement of Science (AAAS)
2023
|
| Online Access: | https://hdl.handle.net/1721.1/147865 |
| _version_ | 1811084930723086336 |
|---|---|
| author | Kaplonek, Paulina Cizmeci, Deniz Fischinger, Stephanie Collier, Ai-ris Suscovich, Todd Linde, Caitlyn Broge, Thomas Mann, Colin Amanat, Fatima Dayal, Diana Rhee, Justin de St Aubin, Michael Nilles, Eric J Musk, Elon R Menon, Anil S Saphire, Erica Ollmann Krammer, Florian Lauffenburger, Douglas A Barouch, Dan H Alter, Galit |
| author2 | Massachusetts Institute of Technology. Department of Biological Engineering |
| author_facet | Massachusetts Institute of Technology. Department of Biological Engineering Kaplonek, Paulina Cizmeci, Deniz Fischinger, Stephanie Collier, Ai-ris Suscovich, Todd Linde, Caitlyn Broge, Thomas Mann, Colin Amanat, Fatima Dayal, Diana Rhee, Justin de St Aubin, Michael Nilles, Eric J Musk, Elon R Menon, Anil S Saphire, Erica Ollmann Krammer, Florian Lauffenburger, Douglas A Barouch, Dan H Alter, Galit |
| author_sort | Kaplonek, Paulina |
| collection | MIT |
| description | <jats:p>The successful development of several coronavirus disease 2019 (COVID-19) vaccines has substantially reduced morbidity and mortality in regions of the world where the vaccines have been deployed. However, in the wake of the emergence of viral variants that are able to evade vaccine-induced neutralizing antibodies, real-world vaccine efficacy has begun to show differences across the two approved mRNA platforms, BNT162b2 and mRNA-1273; these findings suggest that subtle variation in immune responses induced by the BNT162b2 and mRNA-1273 vaccines may confer differential protection. Given our emerging appreciation for the importance of additional antibody functions beyond neutralization, we profiled the postboost binding and functional capacity of humoral immune responses induced by the BNT162b2 and mRNA-1273 vaccines in a cohort of hospital staff. Both vaccines induced robust humoral immune responses to wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to variants of concern. However, differences emerged across epitope-specific responses, with higher concentrations of receptor binding domain (RBD)– and N-terminal domain–specific IgA observed in recipients of mRNA-1273. Antibodies eliciting neutrophil phagocytosis and natural killer cell activation were also increased in mRNA-1273 vaccine recipients as compared to BNT162b2 recipients. RBD-specific antibody depletion highlighted the different roles of non–RBD-specific antibody effector functions induced across the mRNA vaccines. These data provide insights into potential differences in protective immunity conferred by these vaccines.</jats:p> |
| first_indexed | 2024-09-23T12:59:53Z |
| format | Article |
| id | mit-1721.1/147865 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T12:59:53Z |
| publishDate | 2023 |
| publisher | American Association for the Advancement of Science (AAAS) |
| record_format | dspace |
| spelling | mit-1721.1/1478652023-02-04T03:24:19Z mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions Kaplonek, Paulina Cizmeci, Deniz Fischinger, Stephanie Collier, Ai-ris Suscovich, Todd Linde, Caitlyn Broge, Thomas Mann, Colin Amanat, Fatima Dayal, Diana Rhee, Justin de St Aubin, Michael Nilles, Eric J Musk, Elon R Menon, Anil S Saphire, Erica Ollmann Krammer, Florian Lauffenburger, Douglas A Barouch, Dan H Alter, Galit Massachusetts Institute of Technology. Department of Biological Engineering <jats:p>The successful development of several coronavirus disease 2019 (COVID-19) vaccines has substantially reduced morbidity and mortality in regions of the world where the vaccines have been deployed. However, in the wake of the emergence of viral variants that are able to evade vaccine-induced neutralizing antibodies, real-world vaccine efficacy has begun to show differences across the two approved mRNA platforms, BNT162b2 and mRNA-1273; these findings suggest that subtle variation in immune responses induced by the BNT162b2 and mRNA-1273 vaccines may confer differential protection. Given our emerging appreciation for the importance of additional antibody functions beyond neutralization, we profiled the postboost binding and functional capacity of humoral immune responses induced by the BNT162b2 and mRNA-1273 vaccines in a cohort of hospital staff. Both vaccines induced robust humoral immune responses to wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to variants of concern. However, differences emerged across epitope-specific responses, with higher concentrations of receptor binding domain (RBD)– and N-terminal domain–specific IgA observed in recipients of mRNA-1273. Antibodies eliciting neutrophil phagocytosis and natural killer cell activation were also increased in mRNA-1273 vaccine recipients as compared to BNT162b2 recipients. RBD-specific antibody depletion highlighted the different roles of non–RBD-specific antibody effector functions induced across the mRNA vaccines. These data provide insights into potential differences in protective immunity conferred by these vaccines.</jats:p> 2023-02-03T18:02:02Z 2023-02-03T18:02:02Z 2022 2023-02-03T17:54:52Z Article http://purl.org/eprint/type/JournalArticle https://hdl.handle.net/1721.1/147865 Kaplonek, Paulina, Cizmeci, Deniz, Fischinger, Stephanie, Collier, Ai-ris, Suscovich, Todd et al. 2022. "mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions." Science Translational Medicine, 14 (645). en 10.1126/SCITRANSLMED.ABM2311 Science Translational Medicine Creative Commons Attribution 4.0 International license https://creativecommons.org/licenses/by/4.0/ application/pdf American Association for the Advancement of Science (AAAS) Science Translational Medicine |
| spellingShingle | Kaplonek, Paulina Cizmeci, Deniz Fischinger, Stephanie Collier, Ai-ris Suscovich, Todd Linde, Caitlyn Broge, Thomas Mann, Colin Amanat, Fatima Dayal, Diana Rhee, Justin de St Aubin, Michael Nilles, Eric J Musk, Elon R Menon, Anil S Saphire, Erica Ollmann Krammer, Florian Lauffenburger, Douglas A Barouch, Dan H Alter, Galit mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions |
| title | mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions |
| title_full | mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions |
| title_fullStr | mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions |
| title_full_unstemmed | mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions |
| title_short | mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions |
| title_sort | mrna 1273 and bnt162b2 covid 19 vaccines elicit antibodies with differences in fc mediated effector functions |
| url | https://hdl.handle.net/1721.1/147865 |
| work_keys_str_mv | AT kaplonekpaulina mrna1273andbnt162b2covid19vaccineselicitantibodieswithdifferencesinfcmediatedeffectorfunctions AT cizmecideniz mrna1273andbnt162b2covid19vaccineselicitantibodieswithdifferencesinfcmediatedeffectorfunctions AT fischingerstephanie mrna1273andbnt162b2covid19vaccineselicitantibodieswithdifferencesinfcmediatedeffectorfunctions AT collierairis mrna1273andbnt162b2covid19vaccineselicitantibodieswithdifferencesinfcmediatedeffectorfunctions AT suscovichtodd mrna1273andbnt162b2covid19vaccineselicitantibodieswithdifferencesinfcmediatedeffectorfunctions AT lindecaitlyn mrna1273andbnt162b2covid19vaccineselicitantibodieswithdifferencesinfcmediatedeffectorfunctions AT brogethomas mrna1273andbnt162b2covid19vaccineselicitantibodieswithdifferencesinfcmediatedeffectorfunctions AT manncolin mrna1273andbnt162b2covid19vaccineselicitantibodieswithdifferencesinfcmediatedeffectorfunctions AT amanatfatima mrna1273andbnt162b2covid19vaccineselicitantibodieswithdifferencesinfcmediatedeffectorfunctions AT dayaldiana mrna1273andbnt162b2covid19vaccineselicitantibodieswithdifferencesinfcmediatedeffectorfunctions AT rheejustin mrna1273andbnt162b2covid19vaccineselicitantibodieswithdifferencesinfcmediatedeffectorfunctions AT destaubinmichael mrna1273andbnt162b2covid19vaccineselicitantibodieswithdifferencesinfcmediatedeffectorfunctions AT nillesericj mrna1273andbnt162b2covid19vaccineselicitantibodieswithdifferencesinfcmediatedeffectorfunctions AT muskelonr mrna1273andbnt162b2covid19vaccineselicitantibodieswithdifferencesinfcmediatedeffectorfunctions AT menonanils mrna1273andbnt162b2covid19vaccineselicitantibodieswithdifferencesinfcmediatedeffectorfunctions AT saphireericaollmann mrna1273andbnt162b2covid19vaccineselicitantibodieswithdifferencesinfcmediatedeffectorfunctions AT krammerflorian mrna1273andbnt162b2covid19vaccineselicitantibodieswithdifferencesinfcmediatedeffectorfunctions AT lauffenburgerdouglasa mrna1273andbnt162b2covid19vaccineselicitantibodieswithdifferencesinfcmediatedeffectorfunctions AT barouchdanh mrna1273andbnt162b2covid19vaccineselicitantibodieswithdifferencesinfcmediatedeffectorfunctions AT altergalit mrna1273andbnt162b2covid19vaccineselicitantibodieswithdifferencesinfcmediatedeffectorfunctions |